11 December 2015 - Regeneron Pharmaceuticals and Sanofi today announced that UnitedHealth Group will provide preferred access to Praluent injection through OptumRx and UnitedHealthcare for Commercial, Medicare, and Managed Medicaid patients. This decision, when combined with prior favorable coverage decisions at Express Scripts, Aetna and other insurers, provides for access to flexible dosing with Praluent on formularies covering more than 100 million patients in the United States.

For more details, go to: http://files.shareholder.com/downloads/REGN/1165597070x0x866311/E9B56B3E-8B81-4ABD-9FFC-1CAED413C0D9/REGN_News_2015_12_11_General_Releases.pdf